Capital City Bank Group, Inc. Reports First Quarter 2017 Results
Apr 24, 2017 11:01 am UTC| Business
TALLAHASSEE, Fla., April 24, 2017 -- Capital City Bank Group, Inc. (Nasdaq:CCBG) today reported net income of $2.7 million, or $0.16 per diluted share for the first quarter of 2017 compared to net income of $3.3...
Apr 24, 2017 11:01 am UTC| Business
VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that two cost benefit analyses presented at the annual meeting of the European Congress of Clinical Microbiology and...
Apr 24, 2017 11:01 am UTC| Business
VIENNA, Austria, April 24, 2017 -- Paratek Pharmaceuticals, Inc. (Nasdaq:PRTK) announced today that two cost benefit analyses presented at the annual meeting of the European Congress of Clinical Microbiology and...
Apr 24, 2017 11:00 am UTC| Business
STAMFORD, Conn., April 24, 2017 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by...
Apr 24, 2017 11:00 am UTC| Business
BEDMINSTER, N.J., April 24, 2017 -- Matinas BioPharma Holdings, Inc. (NYSE MKT:MTNB), a clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today...
Apr 24, 2017 11:00 am UTC| Business
BOSTON, April 24, 2017 -- ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new immunotherapies, today announced that it will host a conference call and webcast slide presentation on Monday,...
XOMA Announces Positive Results from its Phase 2 Proof-Of-Concept Study of Prolactin Inhibition
Apr 24, 2017 11:00 am UTC| Business
BERKELEY, Calif., April 24, 2017 -- XOMA Corporation (Nasdaq:XOMA), a pioneer in the discovery and development of therapeutic antibodies, today announced that it has achieved positive Phase 2 proof-of-concept results...
Tariff Tremors: Trump’s Greenland Fight Rattles Global Markets